ClearPoint Neuro (CLPT)
Enables neurosurgery, laser therapy, CNS delivery, and neurocritical care with navigation tools.
Something off on this page? Send us feedback.
Sells stereotactic navigation systems, disposable devices, laser-therapy access, neurocritical-care fluid management, and CNS-delivery services for neurosurgeons and therapy developers, with recurring procedure use and partner trial progress shaping demand.
Offers neuro-only medical devices and development services for brain and spine procedures. The platform centers on ClearPoint navigation, SmartFrame hardware and software, SmartFlow cannulas, ClearPoint Prism laser therapy, and IRRAflow fluid-management systems added through the IRRAS acquisition.
Runs from Southern California, with activated centers and partner work spanning global clinical and research sites. Revenue comes from product sales, procedure-linked disposables, capital equipment, software, and service work that supports therapy programs from preclinical testing through clinical use.
Execution depends on device clearance and certification, hospital adoption of MRI-suite and operating-room workflows, therapy partners advancing CNS programs, and integration of the neurocritical-care line. Financing needs remain tied to operating losses, R&D, regulatory work, commercial expansion, and acquisition integration.
Company facts
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $29.4M · Total debt $63.9M · Total assets $86.7M · Shareholders' equity $10.8M
- Revenue
- $10.9M
- Operating income
- −$10.2M
- Net income
- −$11.3M
No dividends on record.
| Institutions | ≈ 45.88% | 14.00M shares | |
|---|---|---|---|
| 140 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 3.82% | 1.16M shares | |
| 11 holders · as of Sep 3, 2026 | |||
| Other | ≈ 50.30% | 15.34M shares | |
| remainder | |||
30.50M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 7.80% | 2.38M | as of Jun 30, 2026 |
Mak Capital One LLCInstitution | 7.79% | 2.38M | as of Jun 30, 2026 |
MAK Capital Fund LPInstitution | 6.23% | 1.90M | filed May 15, 2026 |
Vanguard Capital Management LLCInstitution | 4.04% | 1.23M | as of Jun 30, 2026 |
State Street CorpInstitution | 2.68% | 816,547 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 29, 2026 | Joseph Burnett | director, officer: CEO and President | −20,000 | $19.38 |
| Jun 17, 2026 | Joseph Burnett | director, officer: CEO and President | −61,843 | $17.79 |
| Jun 1, 2026 | Timothy T. Richards | director | −5,415 | $12.17 |
| May 21, 2026 | Matthew B. Klein | director | −16,000 | $11.59 |
| May 20, 2026 | Lynnette C. Fallon | director | −5,091 | $11.14 |
- Medtronic
Multi-front rival in neuro navigation, laser ablation, and EVD/ICP
- Zimmer Biomet
OR stereotactic robot alternative for DBS, SEEG, biopsy, and endoscopy
- Stryker
Cranial navigation rival in OR planning and guided instrument placement
- Integra LifeSciences
Neurocritical-care rival in EVD catheters and ICP monitoring
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ClearPoint Neuro | $15.75 | −0.25% | $419.0M | — | — | 9.9 | +18.1% |
| Medtronic | $90.80 | +0.03% | $117.44B | 22.6 | 15.1 | 3.1 | +13.7% |
| Zimmer Biomet | $93.98 | −0.04% | $18.25B | 22.9 | 10.7 | 2.1 | +4.8% |
| Stryker | $275.27 | +0.08% | $105.11B | 28.4 | 17.2 | 4.1 | +9.4% |
| Integra LifeSciences | $16.02 | +0.06% | $1.21B | — | 6.3 | 0.7 | +0.8% |
| Median | 22.9 | 12.9 | 2.6 | +7.1% |